FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

DANVERS, Mass. – September 16, 2022 – Abiomed (Nasdaq: ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella® heart pumps in acute myocardial infarction (AMI) cardiogenic shock patients.